A premium vector and transposon platform delivering higher yields and faster cell line development in CHO and HEK systems.
A premium vector and transposon platform delivering higher yields and faster cell line development in CHO and HEK systems.
2G UNic vector and transposon platform is trusted by leading biotechnology companies and CDMOs worldwide to deliver higher-yield production and improved manufacturing performance across biologics, biosimilars and advanced therapies.
Representative data showing a 4–5× increase in titer across the clonal population for a difficult-to-express bispecific antibody.
Engineered to maximise transcription and translation, delivering consistently higher expression levels
Stronger pools and clones help streamline screening and accelerate cell line development.
Drop-in technology with no changes to host systems, selection or development processes
Used in molecules progressing to the clinic and adopted by leading pharma, biotech and CDMO partners
Engineered to maximise transcription and translation, delivering consistently higher expression levels
Stronger pools and clones help streamline screening and accelerate cell line development.
Drop-in technology with no changes to host systems, selection or development processes
Used in molecules progressing to the clinic and adopted by leading pharma, biotech and CDMO partners
By enhancing both transcription and translation, output is increased at every stage of expression, without the need for high gene copy numbers.
More mRNA per gene copy
More protein per mRNA
2G UNic combines an expression-optimised vector with efficient transposase-mediated integration, delivering higher titers, improved pool and clone performance, and faster cell line development.
By enabling efficient, stable integration, high-producing cell lines are generated faster and more consistently.
More efficient clone screening
Higher yield
Combining optimised expression with efficient integration, the 2G UNic platform delivers consistent increases in expression across monoclonal antibodies and complex biologics.
Across multiple molecules, including monoclonal antibodies and bispecifics, the 2G UNic platform delivers consistent improvements in expression following stable integration.
Accelerating timelines from transfection to stable production.
Enhances expression at the vector level, delivering higher titers, more consistent expression and faster cell line development when used with existing transposon systems.
Enhancing expression within your existing system
Improves transcription and translation at the vector level, increasing expression when combined with transposon-based integration.
This translates into:
Proven in mammalian hosts such as CHO and HEK, and successfully applied in yeast (Pichia pastoris / Komagataella phaffii), the platform supports efficient production of recombinant proteins, enzymes and vaccine antigens.
The same transcriptional and translational enhancements that drive performance in mammalian systems also support productivity in microbial expression.
High-yield transient and stable expression of antibodies, Fc-fusions, and other recombinant proteins.
Rapid, stable generation of high-yield producer and packaging lines for viral-vector manufacturing.
Efficient production of enzymes and vaccine antigens in Pichia pastoris / Komagataella phaffii.
Integrates directly into standard CHO and HEK workflows without requiring proprietary host systems or process redevelopment.
Compatible with common selection markers, vector backbones and transposon systems, enabling rapid evaluation and scale-up across monoclonal antibodies, biosimilars and complex biologics.
Flexible adoption
2G UNic can be implemented in a way that fits your development strategy:
Implementation support – our R&D team can support integration of 2G UNic into your existing platform or workflow
How it can be used
Supported by flexible licensing models to align with your development and commercial strategy.
Achieve 2–5× higher expression across multiple formats, including challenging biologics, with titers >10 g/L.
Reduce screening and move more quickly from transfection to high-producing stable cell lines.
Deliver consistent, long-term expression to support reliable process performance and scale-up.
